CAR T-Cell Tx Durability May Depend on B-ALL Disease Burden – MedPage Today
|
CAR T-Cell Tx Durability May Depend on B-ALL Disease Burden
MedPage Today WASHINGTON — CD19-specific chimeric antigen receptor (CAR) T-cell therapy was more likely to be definitive and curative — rather than just a bridge to stem cell transplant — when given immediately after front-line therapy rather than waiting for … |
